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Overactive bladder (OAB) is characterised by urgency
with or without urge incontinence, usually with uri-
nary frequency and nocturia (1). OAB is a common
condition that affects millions of people worldwide
and OAB-associated urge urinary incontinence (UUI,
‘wet’ OAB) is especially prevalent in older women
(2). This chronic condition signiﬁcantly impairs
quality of life and can seriously degrade various
aspects of daily living (3).
Behavioural therapy is usually the ﬁrst step in
managing OAB, followed by pharmacological therapy
with antimuscarinic drugs that inhibit detrusor activ-
ity. Behavioural programmes typically utilise bladder
training, pelvic ﬂoor muscle training or a combina-
tion of the two techniques to reduce the number of
incontinence episodes, controlling sensations of
urgency and changing voiding habits. Behavioural
training has been shown to have beneﬁt for reducing
UUI in a number of clinical studies (4–8) and offers
an alternative to drugs and surgery for the treatment
of OAB (9).
Although the exact means by which behavioural
training reduces UUI episodes is unclear, the physio-
logical mechanisms involved in producing the beneﬁ-
cial effects are likely to be different from those of
antimuscarinic drugs (9). This observation suggests
that the combination of behavioural training and an-
timuscarinic treatment may have additive beneﬁt for
the management of OAB.
This study was designed to assess the efﬁcacy,
safety and tolerability of darifenacin, an antimuscari-
nic agent with a high relative afﬁnity for the M3
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SUMMARY
Purpose: This study assessed the beneﬁt of adding behavioural modiﬁcation to
darifenacin treatment for overactive bladder (OAB). Materials and methods: The
ABLE trial was a randomised, open-label, parallel-group, multicentre study of
12 weeks of darifenacin treatment [with voluntary up-titration from 7.5 mg once
daily (qd) to 15 mg qd at week 2] alone or in combination with a Behavioural
Modiﬁcation Programme (BMP) for men and women with dry or wet OAB. Efﬁcacy
was assessed as the change in the number (per day) of micturitions (primary vari-
able), urge urinary incontinence (UUI) episodes, urgency episodes, pads used and
nocturnal voids. Health-related quality of life (HRQoL) was also evaluated.
Tolerability and safety assessments included adverse events and the number of
discontinuations. Results: Of 592 patients screened, 395 were randomised, 190
to darifenacin alone and 205 to darifenacin + BMP. At baseline, the majority of
subjects were dry (mean 2.8 and three UUI episodes per day in the darifenacin
and darifenacin + BMP groups respectively). At study end, darifenacin alone and
darifenacin + BMP both produced signiﬁcant reductions from baseline in median
numbers of micturitions, UUI episodes, urgency episodes and nocturnal voids (all
p < 0.05), but not in the number of pads used. HRQoL also improved. There were
no signiﬁcant differences between treatment groups in efﬁcacy or HRQoL variables.
Conclusions: Darifenacin treatment provides a degree of normalisation of micturi-
tion variables and improvement in HRQoL that cannot be further enhanced by
behavioural therapy of the type used in this study. Whether behavioural modiﬁca-
tion would add beneﬁt over darifenacin treatment in patients with more pro-
nounced incontinence problems remains to be determined.
What’s known
• Behavioural therapy is usually the ﬁrst step in
managing overactive bladder, followed by
pharmacological therapy with antimuscarinic
drugs that inhibit detrusor activity.
• Both therapies are known to be effective
independent treatments for OAB.
• Few trials have assessed the value of combining
behavioural and pharmacological therapy.
What’s new
• The study ﬁndings support the use of darifenacin
as an effective agent for reducing the symptoms
of OAB and improving health-related quality of
life.
• The data do not support the hypothesis that
behavioural modiﬁcation of the type used in this
study, adds any signiﬁcant beneﬁt over that
achieved with darifenacin alone for treatment of
the clinical symptoms of OAB, at least in our
study population.
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with a Behavioural Modiﬁcation Programme (BMP)
for treating symptoms of OAB. In an attempt to
reﬂect real clinical practice, the study included both
dry and wet patients.
Patients and methods
This study was conducted in compliance with the
human experimentation guidelines of the US Depart-
ment of Health and Human Services and the Hel-
sinki Declaration, 1975, last amended in Edinburgh,
Scotland, 2000. Written informed consent was
obtained from each study participant.
Patient population and demographics
This was a randomised, open-label, parallel-group,
multicentre study, conducted between 23 May 2005
and 8 February 2006. Male and female patients
‡ 18 years old with symptoms of OAB for at least
6 months were enrolled in 64 US centres. Inclusion
criteria for this study were ‡ 8 micturitions on
average per day, ‡ 2 episodes of UUI on average
per day and⁄or ‡ 2 episodes of urgency on average
per day. Exclusion criteria included use of any drug
that could affect bladder function within 2 weeks
prior and during the study, participation in any
formal bladder-training programme within 30 days
of screening, predominant stress urinary inconti-
nence, and any bladder or neurological condition
that could affect urinary bladder function or in
which use of anticholinergic drugs was contraindi-
cated.
Study design
This multicentre US study was designed to evaluate
the efﬁcacy, safety and tolerability of darifenacin
administered alone or in combination with BMP.
The study consisted of a 2-week washout and 1-week
screening period followed by 12 weeks of treatment
(Figure 1). Patients were instructed to record symp-
toms of OAB in a bladder diary for the three consec-
utive days immediately preceding each evaluation (at
randomisation, and at study weeks 2, 6 and 12), and
patients meeting inclusion and exclusion criteria
were randomly assigned to receive darifenacin treat-
ment either alone or in conjunction with a BMP.
Randomisation was performed by the sponsor using
a validated, computer-generated randomisation
scheme. The randomisation scheme was reviewed by
the sponsor’s Quality Assurance group and locked
after approval.
Darifenacin was taken orally once daily (qd) in
the morning with an adequate amount of ﬂuid.
Patients assigned to the darifenacin plus BMP group
received brochures on modiﬁcation of diet and
daily habits. These patients were trained in pelvic
muscle exercises and urgency control techniques
using materials (listed in Table 1) developed in
conjunction with the National Association for
Continence. The BMP comprised a simple regimen
for which training could be given in a primary
physician’s ofﬁce, including timed voiding, dietary
modiﬁcations and Kegel-type exercises, and was
meant to reﬂect real-life clinical practice. Complex
regimens that would require extensive training or a
trained physical therapist were purposefully avoided
because that would not be practical in primary care.
Study staff at each site reviewed each component of
the BMP with patients.
Patients in both treatment groups initially received
darifenacin 7.5 mg qd, and were allowed to increase
their darifenacin dose to 15 mg qd after 2 weeks of
treatment if the patient required greater efﬁcacy and
Figure 1 A schematic of the study design. BMP, Behavioural Modiﬁcation Programme. *3-day paper diary completed
1 week prior to clinic visit
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7.5 mg qd throughout the study.
Efﬁcacy, safety and tolerability assessments
The primary efﬁcacy variable was the change from
baseline in average number of micturitions per day.
Week 12 was the primary analysis time point, with
additional analyses conducted for weeks 2 and 6.
Secondary efﬁcacy variables included changes from
baseline per day in the following: average number of
UUI episodes; average number of urgency episodes;
average number of urinary incontinence pads used;
average number of nocturnal voids because of OAB.
In addition, health-related quality of life (HRQoL)
was evaluated by the Overactive Bladder Question-
naire (OAB-q) at baseline, Weeks 6 and 12 and
patient satisfaction with treatment at week 12 was
evaluated using the Overactive Bladder Satisfaction
with Treatment Questionnaire (OAB-SAT-q). Results
for the psychometric properties of the OAB-SAT-q
questionnaire and analysis of the modiﬁed Female
Sexual Function Index will be reported elsewhere.
Safety and tolerability were assessed by recording
adverse events (AEs) by severity and relationship to
study drug, and discontinuations.
Statistical methods
Statistical analyses were performed using SAS, Ver-
sion 8.2 (Cary, NJ, USA). All statistical tests
employed a two-sided signiﬁcance level of 0.05. All
statistical analyses were performed on the intent-to-
treat (ITT) population, which includes all rando-
mised patients who took at least one dose of study
medication. For those patients who discontinued
from the study or whose diary entries at week 12
were missing, the ITT analysis was performed using
the last-observation-carried-forward method. If the
diary entries for any variable were missing for at least
two of the required 3 days at weeks 6 and 12, the
average from the previous visit was carried forward
and used in the summaries and analyses. If all diary
entries for a particular variable were missing during
baseline or week 2, the corresponding average value
was considered missing.
All efﬁcacy variables were analysed using the strati-
ﬁed Wilcoxon rank-sum test (van Elteren’s test),
adjusted for baseline severity (three categories
deﬁned by the baseline 33rd and 67th percentiles).
The difference between the two treatment groups
was expressed as the Hodges–Lehmann point esti-
mate and the associated 95% conﬁdence interval
(CI) (11). Planned subgroup analyses of the efﬁcacy
variables were performed for patients who were
‡ 65 years old.
Changes from baseline in the total score and each
dimension⁄domain score of OAB-q and OAB-SAT-q
were analysed using an analysis of covariance model
with treatment group, age, gender and baseline (if
applicable) as explanatory variables.
For the primary efﬁcacy objective, it was assumed
that the probability of observing the same or a more
favourable response on darifenacin + BMP relative
to darifenacin alone, measured using the primary
efﬁcacy variable, was in the range of 0.58–0.59. With
200 patients per group, the power to detect a differ-
ence between the two groups was 79–87%, depend-
ing on the assumed probability and using a two-
sided Wilcoxon rank-sum test with a signiﬁcance
level of 0.05 (12).
Results
Patient disposition
Of 592 patients screened, a total of 395 patients were
randomised, 190 to darifenacin alone, and 205 to
darifenacin + BMP. There were 47 discontinuations
(17 darifenacin, 30 darifenacin + BMP; Figure 2),
most commonly because of AEs (3.2% darifenacin
alone, 10.2% darifenacin + BMP). Five patients
(1.3%; four darifenacin alone, one darifenacin +
BMP) were discontinued from the study because of
protocol violations: non-compliance with study drug
(2), incorrect procedure⁄procedure not done (2), not
meeting the inclusion⁄exclusion criteria (1).
Patient demographics and baseline values
The two treatment groups were comparable (Table 2),
with an average age of 57–59 years and predomi-
nantly female (89%). The mean age of the subgroup
of patients ‡ 65 years old (n = 134, 34%) was
72.9 years and this group was also predominantly
female (84%).
Table 1 Components of the Behavioural Modiﬁcation
Programme
Pamphlets
Take control-incontinence: diagnosis, treatment and
management
Diet and daily habits: can this affect your bladder or
bowel control?
Pelvic muscle exercises: exercises speciﬁcally for the
pelvic ﬂoor




Pelvic ﬂoor training manual
All materials ª NAFC, 2005 (http://www.nafc.org).
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cacy variables are summarised in Table 3. To assess
the severity of incontinence at baseline, the distribu-
tion of average number of UUI episodes per day at
baseline was also examined in both the overall and
‡ 65-year-old subgroup (Table 4). At baseline, the
majority of subjects in both treatment groups and
age subgroups were dry or had few UUI episodes
(> 0 to < 7 episodes).
Figure 2 Patient disposition and ﬂow
Table 2 Patient demographics
Darifenacin Darifenacin + BMP
Randomised (n) 190 205
Mean (SD) age 57.4 (13.06) 58.5 (14.64)




BMP, Behavioural Modiﬁcation Programme; SD, standard devia-
tion.
Table 3 Baseline values of efﬁcacy variables
Darifenacin Darifenacin + BMP
n = 189 n = 204
Micturitions per day
Mean ± SD 11.92 ± 3.03 11.75 ± 3.37
Median 11.33 11.33
UUI episodes per day
Mean ± SD 2.78 ± 2.57 3.00 ± 2.56
Median 2.33 2.58
Urgency episodes per day
Mean ± SD 10.88 ± 3.80 10.58 ± 4.00
Median 10.67 10.33
Pads used per day
Mean ± SD 1.12 ± 1.93 0.99 ± 1.67
Median 0 0
Nocturnal voids per day
Mean ± SD 1.77 ± 1.43 1.87 ± 1.35
Median 1.67 1.67
BMP, Behavioural Modiﬁcation Programme; UUI, urge urinary
incontinence; SD, standard deviation.
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The median of the average number of micturitions
per day in the ITT population decreased from
baseline (11.33 in both treatment groups) to 8.67
for darifenacin alone and 8.67 for darifena-
cin + BMP at week 12. Thus, the median change
from baseline to week 12 in the average number
of micturitions per day was )2.7 (95% CI: )3.3,
)2.0) for darifenacin alone and )2.7 (95% CI:
)3.0, )2.3) for darifenacin + BMP. Signiﬁcant
reductions were recorded at each time point (Fig-
ure 3), but did not differ signiﬁcantly between
treatment groups. Thus, near-normalisation of mic-
turition frequency was achieved at week 2 (median
9.67 micturitions per day in both groups), with
only small further improvements at weeks 6 or 12
(median 8.67 micturitions per day in both groups
at both time points). Results were similar for the
‡ 65-year-old subgroup; the average number of
micturitions per day decreased in both darifenacin
(median change to week 12: )2.7; 95% CI: )3.3,
)1.7) and darifenacin + BMP ()2.8; 95% CI: )3.3,
)2.0) groups with no statistically signiﬁcant differ-
ence between the groups.
At week 12, treatment with darifenacin or darifen-
acin + BMP both resulted in signiﬁcant reduction
from baseline in the median number of UUI epi-
sodes, urgency episodes and nocturnal voids for the
ITT population (i.e. including both wet and dry
patients), but the change in the number of pads used
vs. baseline was not signiﬁcant (Table 5). The reduc-
tions in all parameters were not signiﬁcantly different
between the two treatments.
Health-related quality of life
Both the darifenacin alone and darifenacin + BMP
groups showed improvement in total OAB-q and
total OAB-SAT-q scores at week 12 indicating
improved HRQoL with both treatments. The differ-
ences between the two groups for both the OAB-q
and OAB-SAT-q at week 12 were not signiﬁcant.
Safety and tolerability
Adverse events were comparable between treatments.
The most frequently reported AEs were constipation
(18.5%), dry mouth (25%), urinary tract infection
(4.8%), and headache (3.8%) and most were mild to
moderate in intensity. A substantial proportion
(53.8%) of AEs was considered to be unrelated to
treatment. In total, 27 patients (6.8%) discontinued
the study because of an AE, eight patients (2%)
because of constipation and seven patients (1.8%)
because of dry mouth.
Discussion
This study was designed to collect data on efﬁcacy,
safety and tolerability of darifenacin administered
alone or in conjunction with BMP. As the addition
of BMP to darifenacin did not provide any signiﬁ-
cant additional improvement on OAB symptoms,
these data suggest that darifenacin alone may provide
a degree of improvement that cannot be further
enhanced by behavioural therapy. Although both
behavioural and drug therapies are known to be
effective treatments for OAB independently, there are
relatively few trials assessing the value of combining
these two modes of treatment. Whether behavioural
Table 4 Baseline distribution of average number of
UUI episodes per day in the total intent-to-treat
population and ‡ 65-year-old subgroup
Darifenacin Darifenacin + BMP
Average number of UUI episodes per day
at baseline, n (%)
Total population, n 189 204
0 episodes 36 (19.1) 29 (14.2)
> 0 to < 7 episodes 138 (73.0) 155 (76.0)
‡ 7 to < 14 episodes 15 (7.9) 20 (9.8)
‡ 14 episodes 0 (0.0) 0 (0.0)
‡ 65 years old 53 81
0 episodes 9 (17.0) 8 (9.9)
> 0 to < 7 episodes 40 (75.5) 63 (77.8)
‡ 7 to < 14 episodes 4 (7.5) 10 (12.3)
‡ 14 episodes 0 (0.0) 0 (0.0)
BMP, Behavioural Modiﬁcation Programme; UUI, urge urinary
incontinence.
Figure 3 Median change from baseline in average number
of micturitions per day over the 12 weeks of treatment
with darifenacin or darifenacin plus Behavioural
Modiﬁcation Programme (BMP) for the intent-to-treat
(ITT) population. There was no signiﬁcant difference
between the responses to the two treatments at any of the
assessment time points. *p < 0.05 vs. baseline
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treatment remains to be conﬁrmed, with inconsistent
ﬁndings reported to date (13–16).
Two studies reported no increase with combined
anticholinergic and bladder training, compared with
bladder retraining without anticholinergic therapy
(13,14). In contrast, two studies found that the com-
bination of drugs and behavioural training can pro-
duce more beneﬁt than either therapy alone (15,16).
In one study, community-dwelling women with uro-
dynamic evidence of bladder dysfunction, were
randomised to behavioural treatment, oxybutynin or
placebo and offered the opportunity to crossover
into combined therapy if not satisﬁed after 8 weeks
(15). Twenty-seven subjects (41.5%) from drug ther-
apy alone and eight subjects from behavioural treat-
ment alone crossed to combined treatment, with
both groups achieving an additional improvement in
the reduction of incontinence. However, these results
cannot be considered deﬁnitive based on the small
sample size. The second (multicentre, single-blind)
study compared tolterodine treatment with and with-
out the addition of written information about blad-
der training (16). In this study, the effect on voiding
frequency and volume voided was enhanced by the
combination, but there was no further improvement
in urgency or incontinence episodes. Recently, a
Cochrane review evaluated randomised or quasi-
randomised controlled trials of treatment with anti-
cholinergic drugs for OAB syndrome or UUI in
adults, in which at least one management treatment
group involved a non-drug new therapy, including
BMPs (17). The results regarding bladder training
favoured a combination of anticholinergics with
bladder training compared with anticholinergics dur-
ing treatment even if the difference was not statisti-
cally signiﬁcant.
In the present study, the addition of BMP to dari-
fenacin produced no greater reduction in micturition
frequency or UUI than was seen with darifenacin
alone. One possible explanation for this is that the
mechanisms underlying the two treatment effects,
Table 5 Summary of results for primary and secondary efﬁcacy variables after 12 weeks of treatment with darifenacin
or darifenacin + BMP for the ITT population
Darifenacin Darifenacin + BMP
Comparison n = 184 n = 195
DMicturition episodes per day
Mean ± SD )2.96 ± 2.91 )2.82 ± 2.87
Median (95% CI) )2.67 ()3.33, )2.00) )2.67 ()3.00, )2.33)
H–L difference (95% CI) 0.00 ()0.67, 0.33)
p-value 0.681
DUUI episodes per day
Mean ± SD )1.89 ± 2.29 )2.10 ± 2.32
Median (95% CI) )1.33 (–2.00, )1.00) )2.00 ()2.00, )1.33)
H–L difference (95% CI) 0.33 ()0.00, 0.67)
p-value 0.268
DUrgency episodes per day
Mean ± SD )2.87 ± 3.59 )2.68 ± 3.54
Median (95% CI) )2.33 ()3.00, )1.67) )2.67 ()3.00, )2.00)
H–L difference (95% CI) 0.00 ()0.67, 0.67)
p-value 0.882
DPads used per day
Mean ± SD )0.72 ± 1.54 )0.61 ± 1.28
Median (95% CI) 0 (0, 0) 0 (0, 0)
H–L difference (95% CI) 0.00 (0.00, 0.00)
p-value 0.978
DNocturnal voids per day
Mean ± SD )0.65 ± 1.26 )0.67 ± 1.21
Median (95% CI) )0.67 ()0.67, )0.33) )0.67 ()0.67, )0.33)
H–L difference (95% CI) 0.0 ()0.00, 0.33)
p-value 0.315
BMP, Behavioural Modiﬁcation Programme; ITT, intent-to-treat; D, change from baseline; UUI, urge urinary incontinence;
H–L, Hodges–Lehmann. p-values are based on Wilcoxon rank-sum test, adjusting for baseline severity.
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come of decreasing detrusor contraction, or increas-
ing detrusor stability. Comparing the speciﬁc nature
of the selective M3 receptor blockade provided by
darifenacin, with the more general behavioural (both
physiological and psychological) approach with
BMP, this would seem unlikely. Indeed, both treat-
ments are likely to do more than simply reduce de-
trusor activity. For example, it has been suggested
that additional direct effects of antimuscarinic agents
play a role in their overall therapeutic effects, and
that the reduction of sensory symptoms such as
urgency, may be mostly independent of their effect
upon voiding contractions (18–20).
Another possibility for the lack of additional bene-
ﬁt of BMP was inadequate compliance with the
BMP, although this was not formally assessed in our
study. In a previous retrospective study of 123
women with UUI, 55% of the women either never
started the bladder retraining programme or discon-
tinued it before study completion illustrating the dif-
ﬁculties with compliance faced by clinical trials (20).
Interestingly, Burgio et al. (15) performed a study
in older women (mean age = 69.3 years) and dem-
onstrated some beneﬁt of combining drug and
behavioural therapy. The patient population was
entirely female, older than in the present study and
employed biofeedback techniques as part of the
training regimen (15). In comparison, the present
study population was mostly female (approximately
90%), and the analysis of older patients (‡ 65 years)
did not yield any signiﬁcant ﬁndings to suggest an
additional beneﬁt of BMP in older patients, although
of note, the study was not powered to detect an
effect in the older patient subgroup.
An additional consideration may be that the effec-
tiveness of BMP may differ between different types
of BMP. For example, the completion of patient dia-
ries may themselves confer (albeit to a small extent)
a degree of behavioural training. In this study, such
an effect would have occurred for both patient
groups, thereby reducing the potential for further
beneﬁt by addition of BMP. For formal BMP pro-
grammes, effectiveness would be expected to increase
with intensity of training (with personal tuition
expected to yield better results than paper⁄video
instructions alone), and with subsequent monitoring
and reinforcement of training by the caregiver. In
the present study, training occurred only at baseline
and week 2, and there are no data to conﬁrm consis-
tent application of the behavioural recommenda-
tions. This approach is expected to be consistent
with that used in ‘real-life’ clinical settings.
Finally, it may be that behavioural modiﬁcation
training is more successful in patients with more
pronounced incontinence problems. In our trial
population the baseline mean number of UUI epi-
sodes per day was 2.8 in the darifenacin group, and
3.0 in the darifenacin + BMP group. Thus, there was
limited scope for improvement in either group, and
this is also demonstrated by the ﬁnding that near-
normalisation of micturition frequency was already
achieved by week 2. This relatively ‘dry’ proﬁle of
patients may therefore have further contributed to
the non-signiﬁcance of adding BMP to darifenacin
treatment in this study.
In summary, the ﬁndings of the present study
support the use of darifenacin as an effective
agent for reducing the symptoms of OAB and
improving HRQoL. However, the data do not sup-
port the hypothesis that behavioural modiﬁcation
of the type used in this study, adds any signiﬁcant
beneﬁt over that achieved with darifenacin alone
for treatment of the clinical symptoms of OAB, at
least in our study population. Further studies are
necessary to deﬁne the combination of patient
populations, drugs and behavioural modiﬁcation
regimen that provide optimal reduction of OAB
symptoms.
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